Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78
- PMID: 20231467
- PMCID: PMC2851865
- DOI: 10.1073/pnas.0911991107
Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78
Abstract
The P23H mutation within the rhodopsin gene (RHO) causes rhodopsin misfolding, endoplasmic reticulum (ER) stress, and activates the unfolded protein response (UPR), leading to rod photoreceptor degeneration and autosomal dominant retinitis pigmentosa (ADRP). Grp78/BiP is an ER-localized chaperone that is induced by UPR signaling in response to ER stress. We have previously demonstrated that BiP mRNA levels are selectively reduced in animal models of ADRP arising from P23H rhodopsin expression at ages that precede photoreceptor degeneration. We have now overexpressed BiP to test the hypothesis that this chaperone promotes the trafficking of P23H rhodopsin to the cell membrane, reprograms the UPR favoring the survival of photoreceptors, blocks apoptosis, and, ultimately, preserves vision in ADRP rats. In cell culture, increasing levels of BiP had no impact on the localization of P23H rhodopsin. However, BiP overexpression alleviated ER stress by reducing levels of cleaved pATF6 protein, phosphorylated eIF2alpha and the proapoptotic protein CHOP. In P23H rats, photoreceptor levels of cleaved ATF6, pEIF2alpha, CHOP, and caspase-7 were much higher than those of wild-type rats. Subretinal delivery of AAV5 expressing BiP to transgenic rats led to reduction in CHOP and photoreceptor apoptosis and to a sustained increase in electroretinogram amplitudes. We detected complexes between BiP, caspase-12, and the BH3-only protein BiK that may contribute to the antiapoptotic activity of BiP. Thus, the preservation of photoreceptor function resulting from elevated levels of BiP is due to suppression of apoptosis rather than to a promotion of rhodopsin folding.
Conflict of interest statement
Conflict of interest statement: W.W.H. and the University of Florida have a financial interest in the use of AAV therapies and own equity in a company (AGTC Inc.) that might, in the future, commercialize some aspects of this work. All other authors declare no conflict of interest.
Figures
References
-
- Dryja TP, McEvoy JA, McGee TL, Berson EL. Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2000;41:3124–3127. - PubMed
-
- Goto Y, Peachey NS, Ripps H, Naash MI. Functional abnormalities in transgenic mice expressing a mutant rhodopsin gene. Invest Ophthalmol Vis Sci. 1995;36:62–71. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- EY08571/EY/NEI NIH HHS/United States
- K08 EY018313/EY/NEI NIH HHS/United States
- EY06842/EY/NEI NIH HHS/United States
- R01 EY013280/EY/NEI NIH HHS/United States
- EY11123/EY/NEI NIH HHS/United States
- U10 EY013729/EY/NEI NIH HHS/United States
- EY02162/EY/NEI NIH HHS/United States
- P30 EY008571/EY/NEI NIH HHS/United States
- R01 EY011123/EY/NEI NIH HHS/United States
- R01 EY001919/EY/NEI NIH HHS/United States
- P30 EY002162/EY/NEI NIH HHS/United States
- EY13729/EY/NEI NIH HHS/United States
- EY01919/EY/NEI NIH HHS/United States
- R01 EY020846/EY/NEI NIH HHS/United States
- F32 EY006842/EY/NEI NIH HHS/United States
- P01 HL059412/HL/NHLBI NIH HHS/United States
- R01 EY006842/EY/NEI NIH HHS/United States
- EY013280/EY/NEI NIH HHS/United States
- EY018313/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
